title: [Recent advances in allergic rhinitis].
abstract: Allergic rhinitis (AR) clinically expressed by sneezing, rhinorrhea, nasal itching and congestion is an allergen-driven mucosal inflammatory disease which is modulated by immunoglobulin E. Epidemiological studies have indicated that prevalence of AR continues to increase, and it has been a worldwide health problem that places a significant healthcare burden on individuals and society. Given the evolving understanding of the process by which an allergen is recognized and the roles of mediators which account for AR progress, the pathogenesis of AR has become clearer. Current studies have demonstrated local allergic rhinitis (LAR) that patients with both sug- gestive symptoms of AR and a negative diagnostic test for atopy may have local allergic inflammation is a prevalent entity in patients evaluated with rhinitis, but further research remains needed. Management of AR includes aller- gen avoidance, pharmacological treatment and allergen-specific immunotherapy. Recently montelukast has exhibited previously undocumented anti-inflammatory properties, leukotriene receptor antagonists therefore may serve a more important role in the treatment of AR. Not only has immunotherapy proved its efficacy, but also been able to alter disease course and thereby mitigate progression to asthma. Thus immunotherapy can be initiated while receiving pharmacotherapy, especially in children with AR. As clinical guidelines, the ARIA (Allergic Rhinitis and its Impact on Asthma) provides basic principles of effective treatment of AR. Besides, choosing an appropriate treatment strategy should be based on the severity and chronicity of patient's symptom. The aim of this review was to provide an update mainly on the pathophysiology, epidemiology, and management of AR.
authors.forename: Meijun
authors.initials: M
authors.lastname: Liang
authors.forename: Rui
authors.initials: R
authors.lastname: Xu
authors.forename: Geng
authors.initials: G
authors.lastname: Xu
mesh_terms: D000085:Acetates / Q000627:therapeutic use; D000485:Allergens; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000517:prevention & control; D002648:Child; D003521:Cyclopropanes; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000175:diagnosis / Q000503:physiopathology; D007073:Immunoglobulin E / Q000276:immunology; D007167:Immunotherapy; D007249:Inflammation / Q000503:physiopathology; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D015995:Prevalence; D011804:Quinolines / Q000627:therapeutic use; D065631:Rhinitis, Allergic / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology*; D013440:Sulfides
chemical_list: D000085:Acetates; D000485:Allergens; D000893:Anti-Inflammatory Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D007073:Immunoglobulin E; C093875:montelukast